Search

Displaying results 4881 - 4890 of 5383 in total
  1. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. … Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not affected by propylhexedrine.

  2. Drug

    GRAd-COV2

    go.drugbank.com/drugs/DB16428
    Investigational

    GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423].

  3. Drug

    BB-301

    go.drugbank.com/drugs/DB17011
    Investigational

    [A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062]

  4. Drug

    Arsthinol

    go.drugbank.com/drugs/DB08928
    Experimental

    Arsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol.

  5. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  6. Drug

    1D-myo-inositol 1,4,5-trisphosphate

    go.drugbank.com/drugs/DB03401
    Experimental

    Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane.

  7. Drug

    Xanthine

    go.drugbank.com/drugs/DB02134
    Investigational

    It is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine.

  8. Drug

    Cilobradine

    go.drugbank.com/drugs/DB20039
    Investigational

    Cilobradine is under investigation in clinical trial NCT02264041 (Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine).

  9. Drug

    Candoxatrilat

    go.drugbank.com/drugs/DB11623
    Experimental

    A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy

  10. Drug

    Sifalimumab

    go.drugbank.com/drugs/DB12773
    Investigational

    Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.